Refractory malignant neoplasm
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant neoplasm that does not respond to treatment.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Refractory malignant neoplasm
- Therapeutic area
- Oncology
- refractory malignant neoplasm
- refractory cancer
- refractory malignant neoplasm
- resistant cancer
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0036501
- Parent condition
- MONDO:0004992
Related records
Broader conditions (7)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (1)
- Testis refractory cancer
Trials (76)
- 9-ING-41 in Patients With Advanced Cancers
- 9-ING-41 in Pediatric Patients With Refractory Malignancies.
- A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer
- A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
- A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
- A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.
- A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
- A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
- A Study of Avutometinib for People With Solid Tumor Cancers
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
- A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
- A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
- A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
- A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
- Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents
Drugs in development (3)
- Afatinib Phase 2
- Rivoceranib Phase 2
- VLX-600 Phase 1